Indaptus Therapeutics, Inc.
INDP
$6.52
-$0.55-7.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.40% | -25.10% | -21.14% | -17.10% | 18.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.47% | 15.96% | -0.19% | -26.04% | 17.56% |
| Operating Income | -8.47% | -15.96% | 0.19% | 26.04% | -17.56% |
| Income Before Tax | -30.22% | -19.06% | -3.20% | 21.76% | -23.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.22% | -19.06% | -3.20% | 21.76% | -23.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.22% | -19.06% | -3.20% | 21.76% | -23.73% |
| EBIT | -8.47% | -15.96% | 0.19% | 26.04% | -17.56% |
| EBITDA | -8.46% | -15.98% | 0.18% | 26.04% | -17.57% |
| EPS Basic | 30.88% | 28.72% | 20.64% | 30.88% | -21.67% |
| Normalized Basic EPS | 30.88% | 28.72% | 20.64% | 30.88% | -21.67% |
| EPS Diluted | 30.88% | 28.72% | 20.64% | 30.88% | -21.67% |
| Normalized Diluted EPS | 30.88% | 28.72% | 20.64% | 30.88% | -21.67% |
| Average Basic Shares Outstanding | 88.43% | 67.06% | 30.07% | 13.23% | 1.70% |
| Average Diluted Shares Outstanding | 88.43% | 67.06% | 30.07% | 13.23% | 1.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |